NVAX Share Price Performance
US$6.57
-2.66 (-28.82%)
73.7% undervalued intrinsic discount
US$25.00
Fair Value
Price US$6.57
AnalystHighTarget US$25.00
AnalystLowTarget US$6.00
AnalystConsensusTarget US$13.11
Fair ValueUS$25.00
Share Pricen/a
Novavax, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 112 Fair Values set on narratives written by author
NVAX Community Narratives
AN
Fair Value US$25 73.7% undervalued intrinsic discount
Pandemic Preparedness Will Drive Next-Generation Vaccine Opportunities Amid Challenges
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value US$6 9.5% overvalued intrinsic discount
Heightened Regulation And A Narrow Portfolio Will Shrink Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$13.11 49.9% undervalued intrinsic discount
Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead
0users have liked this narrative
0users have commented on this narrative
52users have followed this narrative
Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead
Key Takeaways Strategic partnerships and a leaner operating model are expected to boost profitability and enable new high-margin, recurring revenue streams. Successful vaccine commercialization and platform validation open opportunities in underserved markets and future licensing deals.Read more
0users have liked this narrative
0users have commented on this narrative
52users have followed this narrative
AN
US$13.11
49.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-30.72% p.a.
Profit Margin
15.19%
Future PE
50.93x
Price in 2028
US$16.14
Pandemic Preparedness Will Drive Next-Generation Vaccine Opportunities Amid Challenges
Key Takeaways Strategic partnerships and innovative platforms are set to diversify revenue streams and enhance Novavax's long-term profitability across global vaccine markets. Accelerated demand for combination and next-generation vaccines, alongside increased government focus on preparedness, positions Novavax for durable growth and recurring high-margin income.Read more
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
US$25
73.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
-34.25% p.a.
Profit Margin
12.53%
Future PE
134.6x
Price in 2028
US$30.54
Heightened Regulation And A Narrow Portfolio Will Shrink Margins
Key Takeaways Heavy reliance on a limited vaccine portfolio and partners increases vulnerability to market saturation, operational risks, and diminishing revenue after short-term gains. Intensifying regulatory scrutiny and competition from larger players threaten margins, limit growth opportunities, and hinder Novavax's long-term profitability.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$6
9.5% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
-53.99% p.a.
Profit Margin
16.25%
Future PE
72.61x
Price in 2028
US$7.32
Trending Discussion
Recently Updated Narratives
AN
NVAX: Shifting To Licensing Will Drive Royalties And Upfront Payments
Fair Value: US$13.11 49.9% undervalued intrinsic discount
52 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Heightened Regulation And A Narrow Portfolio Will Shrink Margins
Fair Value: US$6 9.5% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pandemic Preparedness Will Drive Next-Generation Vaccine Opportunities Amid Challenges
Fair Value: US$25 73.7% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Novavax, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 2.10
- 59.42%
- 32.10%
- -155.6%
About NVAX
- Founded
- 1987
- Employees
- 952
- CEO
- WebsiteView website
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
